Gene Therapy Approaches to Enhance Antitumor Immunity

Advances in Pharmacology

Volumn 40, Issue C, 1997, Pages 309-337

  Shawler, Daniel L ^a   Fakhrai, Habib ^a   Van Beveren, Charles ^a   Mercola, Dan ^a   Gold, Daniel P ^a   Bartholomew, Richard M ^b   Royston, Ivor ^a   Sobol, Robert E ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b Orchestra Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; REVIEW;

ANIMALS; CYTOKINES; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030631615     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60143-X     Document Type: Article

References (87)

1. Alleva D.G., Burger C.J., and Elgert K.D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J. Immunol. 153 (1994) 1674-1686
2. Allione A., Consalvo M., Nanni P., Lollini P.L., Cavallo F., Giovarelli M., Forni M., Gulino A., Colombo M.P., Dellabona P., Hock H., Blankenstein T., Rosenthal F.M., Gansbacher B., Bosco M.C., Musso T., Gusella L., and Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gammainterferon gene or admixed with conventional adjuvants. Cancer Res. 54 (1994) 6022-6026
3. Anzano M.A., Rieman D., Prichett W., Bowen-Pope D.F., and Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res.; 49 (1989) 2898-2904
4. Azuma M., Yssel H., Phillips J.H., Spits H., and Lanier L.L. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177 (1993) 845-850
5. Bach N.L., Waks T., Schindler D.G., and Eshhar Z. Functional expression in mast cells of chimeric receptors with antibody specificity. Cell Biophys. 24-25 (1994) 229-236
6. Baskar S., Ostrand-Rosenberg S., Nabavi N., Nadler L.M., Freeman G.J., and Glimcher L.H. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 5687-5690
7. Boel P., Wildmann C., Sensi M.L., Brasseur R., Renauld J.C., Coulie P., Boon T., and van der Bruggen P. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2 (1995) 167-175
8. Borden E.C., and Sondel P.M. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer (Philadelphia) 65 Suppl. 3 (1990) 800-814
9. Brichard V., van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., Coulie P., and Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178 (1993) 489-495
10. Bubenik J., Viotenok N.N., Kieler J., Prassolov V.S., Chumakov P.M., Bubenikova D., Simova J., and Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol. Lett. 19 (1988) 279-282
11. Chen Q., Smith M., Nguyen T., Maher D.W., and Hersey P. T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells. Cancer Immunol. Immunother. 38 (1994) 385-393
12. Coffey Jr. R.J., Goustin A.S., Soderquist A.M., Shipley G.D., Wolfshohl J., Carpenter G., and Moses H.L. Transforming growth factor alpha and beta expression in human colon cancer lines: Implications for an autocrine model. Cancer Res. 47 (1987) 4590-4594
13. Conry R.M., LoBuglio A.F., Loechel F., Moore S.E., Sumerel L.A., Barlow D.L., Pike J., and Curiel D.T. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther. 2 (1995) 33-38
14. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., and Slingluff Jr. C.L. Identification of a peptide recognized by five melanoma specific human cytotoxic T cell lines. Science 264 (1994) 716-719
15. Crowley N.J., Slingluff Jr. C.L., Darrow T.L., and Seigler H.F. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res. 50 (1990) 492-498
16. De Plaen E., Arden K., Traversari C., Gaforio J.T., Szikora J.P., De Smet C., Brasseur F., van der Bruggen P., Lethé B., Lurquin C., Brasseur R., Chomez P., De Backer O., Cavnee W., and Boon T. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40 (1994) 360-369
17. Disis M.L., Calenoff E., McLaughlin G., Murphy A.E., Chen W., Groner B., Jeschke M., Lydon N., McGlynn E., and Livingston R.B. Existent T cell and antibody immunity to HER2/neu protein in patients with breast cancer. Cancer Res. 54 (1994) 16-20
18. Disis M.L., Smith J.W., Murphy A.E., Chen W., and Cheever M.A. In vitro generation of human cytolytic T cells specific for peptides derived from the HER2/neu protooncogene protein. Cancer Res. 54 (1995) 1071-1076
19. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 3539-3543
20. Eshhar Z., and Gross G. Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: A model system for immunotherapeutical approach. Br. J. Cancer 10 Suppl. (1990) 27-29
21. Fakhrai H., Shawler D.L., Gjerset R., Naviaux R.K., Koziol J., Royston I., and Sobol R.E. Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther.; 6 (1995) 591-601
22. Fakhrai H., Dorigo O., Shawler D.L., Lin H., Mercola D., Black K.L., Royston I., and Sobol R.E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2909-2914
23. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., Karasu-yama H., Vogelstein B., and Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell (Cambridge, Mass.) 60 (1990) 387-403
24. Finn O.J. Tumor-rejection antigens recognized by T lymphocytes. Curr. Opin. Immunol. 5 (1993) 701-708
25. Finn O.J., Jerome K.R., Henderson R.A., Pecher G., Domenech N., Magarian-Blander J., and Barratt-Boyes S.M. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145 (1995) 61-89
26. Fossum B., Gedde-Dahl III T., Breivik J., Eriksen J.A., Spurkland A., Thorsby E., and Gaudernack G. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly Asp). Int. J. Cancer 56 (1994) 40-45
27. Freeman G.J., Freedman A.S., Segil J.M., Lee G., Whitman J.F., and Nadler L.M. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143 (1989) 2714-2722
28. Gabrilove J.L., and Jakubowski A. Hematopoietic growth factors: Biology and clinical application. Monogr. J. Natl. Cancer Inst. 10 (1990) 73-77
29. Gandolfi L., Solmi L., Pizza G.C., Bertoni F., Muratori R., DeVinci C., Bacchini P., Morelli M.C., and Corrado G. Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepato-Gastroenterology 36 (1989) 352-356
30. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., and Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172 (1990) 1217-1223
31. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., Lethe B., Brasseur F., and Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179 (1994) 921-930
32. Gross G., and Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6 (1992) 3370-3378
33. Herlyn D., Linnenbach A., Koprowski H., and Herlyn M. Epitope- and antigenspecific cancer vaccines. Int. Rev. Immunol. 7 (1991) 245-257
34. Herlyn D., Harris D., Zaloudik J., Sperlagh M., Maruyama H., Jacob L., Kieny M.-P., Scheck S., Somasundaram R., Hart E., Ertl H., and Mastrangelo M. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J. Immunother. 15 (1994) 303-311
35. Hodge J.W., McLaughlin J.P., Abrams S.I., Shupert W.L., Schlom J., and Kantor J.A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55 (1995) 3598-3603
36. Hollingsworth S., Gaken J., Darling D., Hirst W., Kuiper M., Buggins A., Barnard A., Peakman M., Humphries S., Mufti G.J., and Farzaneh F. Induction of tumour rejection by combination B7.1/IL-2 expressing tumor cells. Cancer Gene Ther. 2 (1995) 240
37. Hwu P., Yang J.C., Cowherd R., Treisman J., Shafer G.E., Eshhar Z., and Rosenberg S.A. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55 (1995) 3369-3373
38. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., McKenzie I.F., Bast Jr. R.C., and Finn O.J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51 (1991) 2908-2916
39. Jubelirer S.J., Talkington A., and Bailey D. Hepatocellular carcinoma: A review of 30 years of experience. W. Va. Med. J. 87 (1991) 400-402
40. June C.H., Ledbetter J.A., Linsley P.S., and Thompson C.B. Role of the CD28 receptor in T-cell activation. Immunol. Today 11 (1990) 211-216
41. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., Miki T., and Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3515-3519
42. Kelso A. Cytokines: Structure function and synthesis. Curr. Opin. Immunol. 2 (1989) 215-225
43. Khanna R., Burrows S.R., Argaet V., and Moss D.J. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 6 (1994) 639-645
44. Khanna R., Burrows S.R., and Moss D.J. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59 (1995) 387-405
45. Kim J.A., Martin Jr. E.W.E.W., Morgan C.J., Aldrich W., and Triozzi P.L. Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer. Cancer Biother. 10 (1995) 115-123
46. Kim T.S., and Cohen E.P. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 54 (1994) 2531-2535
47. Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.J., and Rosenberg S.A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity and histologic findings. JAMA, J. Am. Med. Assoc. 256 (1986) 3117-3124
48. Mackiewicz A., Wiznerowicz M., Roeb E., Nowak J., Pawlowski T., Baumann H., Heinrich P.C., and Rose-John S. Interleukin-6-type cytokines and their receptors for gene therapy of melanoma. Ann. N.Y. Acad. Sci. 762 (1995) 361-373
49. Marincola F.M., Ettinghausen S., Cohen P.A., Cheshire L.B., Restifo N.P., Mulé J.J., and Rosenberg S.A. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J. Immunol. 152 (1994) 3501-3513
50. McBride W.H., Dougherty G.D., Wallis A.E., Economou J.S., and Chiang C.S. Interleukin-3 in gene therapy of cancer. Folia Biol. Praha. 40 (1994) 62-73
51. Mondino A., and Jenkins M.K. Surface proteins involved in T cell costimulation. J. Leukocyte Biol. 55 (1994) 805-815
52. Morioka N., Kikumoto Y., Hoon D.S., Morton D.L., and Irie R.F. A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J. Immunol. 153 (1994) 5650-5658
53. Myers R.B., Schlom J., Srivastava S., and Grizzle W.E. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Mod. Pathol. 8 (1995) 260-265
54. Nabel G.J., Nabel E.G., Yang Z.-Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., and Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11307-11311
55. Nakao M., Yamana H., Imai Y., Toh Y., Toh U., Kimura A., Yanoma S., Kakegawa T., and Itoh K. HLA-A2601 restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res. 55 (1995) 4248-4252
56. Pandolfi F., Boyle L.A., Trentin L., Kurnick J.T., Isselbacher K.J., and Gattoni-Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 51 (1991) 3164-3170
57. Pattengale P.K., and Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell [Cambridge, Mass.) 57 (1989) 503-512
58. Peace D.J., Chen W., Nelson H., and Cheever M.A. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol. 146 (1991) 2059-2065
59. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., and Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54 (1994) 2218-2222
60. *0201-binding peptides. J. Immunol. 154 (1995) 5934-5943
61. Rimoldi D., Romero P., and Carrel S. The human melanoma antigen encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int. J. Cancer 54 (1993) 527-528
62. Robbins P.F., el Gamil M., Kawakami Y., Stevens E., Yannelli J.R., and Rosenberg S.A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54 (1994) 3124-3126
63. Rosenberg S.A., Lotze M.T., and Mulé J.J. New approaches to the immunotherapy of cancer. Ann. Intern. Med. 108 (1988) 853-864
64. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L., Merino M.J., Culver K., Miller A.D., Blaese R.M., and Anderson W.F. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323 (1990) 570-578
65. Russell S.J., Collins M.K., and Cohen E.P. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int. J. Cancer 51 (1992) 283-289
66. Sarna G., Collins J., Figlin R., Robertson P., Altrock B., and Abels R. A pilot study of intralymphatic interleulcin-2. II. Clinical and biological effects. J. Biol. Response Modifiers 9 (1990) 81-86
67. Sawamura Y., Diserens A.C., and de Tribolet N. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J. Neuro-Oncol. 9 (1990) 125-130
68. Schlebusch H., Wagner U., Grunn U., and Schultes B. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 14 (1995) 167-174
69. Sensi M., Traversare C., Radrizzani M., Salvi S., MacCalli C., Mortarini R., Rivoltini L., Farina C., Nicolini G., Wolfel T., Brichard V., Boon T., Bordignon C., Anichini A., and Parmiani G. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5674-5678
70. Shawler D.L., Dorigo O., Gjerset R., Royston I., Sobol R.E., and Fakhrai H. Comparison of gene therapy with interleukin-2 (IL-2) gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J. Immunother. 17 (1995) 201-208
71. Slingluff Jr. C.L., Cox A.L., Henderson R.A., Hunt D.F., and Engelhard V.H. Recognition of human melanoma cells by HLA-A2.1 restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 150 (1993) 2955-2963
72. Slingluff Jr. C.L., Cox A.L., Stover Jr. J.M., Moore M.M., Hunt D.F., and Engelhard V.H. Cytotoxic T lymphocyte response to autologous human squamous cell cancer of the lung: Epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res. 54 (1994) 2731-2737
73. Sobol R.E., Fakhrai H., Shawler D.L., Gjerset R., Dorigo O., Carson C., Khaleghi T., Koziol J., Shiftan T.A., and Royston I. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2 (1995) 164-167
74. Stancovski I., Schindler D.G., Waks T., Yarden Y., Sela M., and Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151 (1993) 6577-6582
75. Stoppacciaro A., Melani C., Parenza M., Mastracchio A., Bassi C., Baroni C., Parmiani G., and Colombo M.P. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J. Exp. Med. 178 (1993) 151-161
76. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv. Cancer Res. 60 (1993) 247-267
77. Tahara H., Zeh III H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., Wolf S.F., Robbins P.D., and Lotze M.T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54 (1994) 182-189
78. Theobald M., Biggs J., Dittmer D., Levine A.J., and Sherman L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11993-11997
79. Topalian S.L., Rivoltini L., Mancini M., Markus N.R., Robbins P.F., Kawakami Y., and Rosenberg S.A. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9461-9465
80. Townsend S.E., and Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259 (1993) 368-370
81. Trojan J., Johnson T.R., Rudin S.D., Ilan J., and Tykocinski M.L. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259 (1993) 94-97
82. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.R., Martinez D., Perry H.C., Shiver J.W., Montgomery D.L., and Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
83. van der Bruggen P., Traversare C., Chmez P., Lurquin C., De Plaen E., van den Eyde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1645
84. Vieweg J., Boczkowski D., Roberson K.M., Edwards D.W., Philip M., Philip R., Rudoll T., Smith C., Robertson C., and Gilboa E. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55 (1995) 2366-2372
85. Wahl W.L., Strome S.E., Nabel G.J., Plautz G.E., Cameron M.J., San H., Fox B.A., Shu S., and Chang A.E. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene. J. Immunother. 17 (1995) 1-11
86. Watanabe Y., Kuribayashi K., Miyatake S., Nishihara K., Nakayama E.L., Taniyama T., and Sakata T.A. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 9456-9460
87. Yoshino I., Goedegebuure P.S., Peoples G.E., Parikh A.S., DiMaio J.M., Lyerly H.K., Gazdar A.F., and Eberlein T.J. HER-2/neu derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54 (1994) 3387-3390